Search

Syndax Pharmaceuticals Inc

Closed

SectorHealthcare

17.25 -4.43

Overview

Share price change

24h

Current

Min

17.69

Max

18.32

Key metrics

By Trading Economics

Income

-6.7M

-49M

Sales

7.9M

73M

EPS

-0.55

Profit margin

-67.817

Employees

298

EBITDA

-5.9M

-37M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+103.45% upside

Dividends

By Acuity

Next Earnings

2 lis 2026

Market Stats

By TradingEconomics

Market Cap

-66M

1.6B

Previous open

21.68

Previous close

17.25

News Sentiment

By Acuity

69%

31%

298 / 339 Ranking in Healthcare

Syndax Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 wrz 2026, 20:07 UTC

Syndax Pharmaceuticals Inc shares are lower amid a broader market decline following a sharp drop in the NY Empire State Manufacturing Index for September.

11 wrz 2026, 19:36 UTC

News

Syndax Pharmaceuticals is lower today, continuing a downward trend amid heightened market volatility following the August Consumer Price Index release.

10 wrz 2026, 20:03 UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a decline since Wednesday's close, with no specific news identified to explain the movement.

8 wrz 2026, 20:07 UTC

News

Syndax Pharmaceuticals is lower today amid broader market weakness and speculation about a Federal Reserve interest rate hike following strong labor data.

2 wrz 2026, 20:08 UTC

Syndax Pharmaceuticals Inc shares are higher today, despite earlier pulling back from a session high amid broader market volatility and slower job growth indicators.

1 wrz 2026, 20:09 UTC

News

Syndax Pharmaceuticals shares are higher as the company announces participation in two investor conferences to boost visibility for its cancer therapies.

25 sie 2026, 19:26 UTC

Syndax Pharmaceuticals Inc shares are higher today, maintaining gains since Monday. The stock remains above the 20-day moving average amid declining yields.

24 sie 2026, 19:51 UTC

Syndax Pharmaceuticals Inc is trading lower, breaking a trend of higher closes. Broader market sentiment is impacted by concerns over U.S.-Iran relations and oil supply disruptions.

21 sie 2026, 19:21 UTC

Syndax Pharmaceuticals shares are lower today, breaking a trend of higher closes since Thursday. The broader market faces volatility amid rising crude oil prices.

20 sie 2026, 20:02 UTC

Correlated Moves

Syndax trades lower amid decline in SPDR S&P Biotech ETF.

19 sie 2026, 19:27 UTC

Correlated Moves

SNDX higher today, supported by strong biotechnology sector performance.

18 sie 2026, 19:56 UTC

Syndax Pharmaceuticals is trading higher today, despite pulling back from earlier session gains. The stock remains positioned near the lower end of its one-month range.

17 sie 2026, 19:36 UTC

Correlated Moves

Shares higher today as iShares Biotechnology ETF also gains.

14 sie 2026, 19:26 UTC

Syndax Pharmaceuticals Inc shares are trading higher during Friday's session, reflecting positive market sentiment despite broader concerns over a decline in U.S. retail sales.

12 sie 2026, 19:31 UTC

Syndax Pharmaceuticals shares are lower, reversing a recent trend of gains. No specific news was identified to explain the decline.

11 sie 2026, 19:26 UTC

News

SNDX trades lower after JPMorgan cuts price target to $40.00.

10 sie 2026, 19:36 UTC

Syndax Pharmaceuticals shares are lower amid broader market volatility and rising oil prices due to geopolitical tensions in the Strait of Hormuz.

6 sie 2026, 19:36 UTC

News

Syndax Pharmaceuticals is lower today, facing volatility amid broader market conditions and recent economic data impacting Federal Reserve policy.

5 sie 2026, 20:02 UTC

News
Social Media

Syndax Pharmaceuticals shares rise after H.C. Wainwright maintains Buy rating and lowers price target to $38, citing strong revenue growth of $73 million.

4 sie 2026, 23:11 UTC

News

Syndax Pharmaceuticals shares are lower in after-market hours following a second-quarter earnings miss, reporting a net loss of $49.4 million and revenue of $72.8 million.

3 sie 2026, 19:16 UTC

Correlated Moves

Syndax Pharmaceuticals Inc shares are higher amid a broader market rally. The stock remains below its 20-day moving average and near the lower end of its one-month range.

31 lip 2026, 20:06 UTC

Correlated Moves

Syndax Pharmaceuticals Inc shares declined after first-quarter results showed lower performance. Broader market pressures from rising yields and oil prices contributed to the decline.

30 lip 2026, 17:06 UTC

Syndax Pharmaceuticals shares are higher as the broader market recovers, with the S&P 500 advancing following recent volatility in U.S. Treasury yields.

29 lip 2026, 19:56 UTC

Macro Event

Syndax Pharmaceuticals Inc shares are lower, continuing a trend with six consecutive daily declines amid broader market concerns over rising crude oil prices.

28 lip 2026, 20:51 UTC

Syndax Pharmaceuticals Inc is trading lower in after-market hours, continuing a six-session decline amid market focus on the Federal Reserve's interest rate decision.

27 lip 2026, 20:06 UTC

Syndax Pharmaceuticals shares are lower as the broader market declines amid falling oil prices, impacting Treasury yields and investor sentiment.

24 lip 2026, 19:52 UTC

Syndax Pharmaceuticals Inc shares are lower today, continuing a downward trend over the past few days amid broader market pressures.

22 lip 2026, 19:06 UTC

Syndax Pharmaceuticals Inc shares are lower today with no specific news identified. Broader market sentiment is impacted by rising crude oil prices and geopolitical tensions.

Peer Comparison

Price change

Syndax Pharmaceuticals Inc Forecast

Price Target

By TipRanks

103.45% upside

12 Months Forecast

Average 37.333 USD  103.45%

High 57 USD

Low 26 USD

Based on 10 Wall Street analysts offering 12 month price targets forSyndax Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

10

Buy

0

Hold

0

Sell

Sentiment

By Acuity

298 / 339 Ranking in Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
help-icon Live chat